Long-term Low-Molecular-Weight Heparin and the Post-Thrombotic Syndrome: A Systematic Review Russell D. Hull, MBBS, MSc, Jane Liang, MSc, Grace Townshend, MSc The American Journal of Medicine Volume 124, Issue 8, Pages 756-765 (August 2011) DOI: 10.1016/j.amjmed.2011.02.033 Copyright © 2011 Elsevier Inc. Terms and Conditions
Figure 1 Risk ratios for the (A) presence of venous ulcers and (B) absence of complete recanalization of thrombosed veins or complete lysis of thrombus, after treatment with long-term low-molecular-weight heparin or oral anticoagulation. A ratio of < 1 favors tinzaparin. Both were calculated using a fixed-effect model. For ulcers: Daskalopoulos et al's trial:24 6-mo therapy with tinzaparin and follow-up at 1 y; Hull et al's study:11 3-mo therapy with tinzaparin and follow-up at 3 mo. For recanalization: Values are those reported for follow-up at 6 mo for Romera et al19 and 3 mo for all the other studies. For López-Beret et al,26 values reported for the popliteal vein were used. Values for the common and superficial femoral veins would have favored low-molecular-weight heparin to an even greater extent (Table 3). CI = confidence interval; LMWH = low-molecular-weight heparin; OA = oral anticoagulant. The American Journal of Medicine 2011 124, 756-765DOI: (10.1016/j.amjmed.2011.02.033) Copyright © 2011 Elsevier Inc. Terms and Conditions